STAAR Surgical CEO to Retire in March 2015
"Barry has done a terrific job of transforming STAAR into the strong, solidly based growth company it is today," said
"During the past seven years, our team has achieved many milestones, dramatically improved the financial performance of STAAR, and generated significant returns to our shareholders," said Mr. Caldwell. "At the same time, I've reached a point in my life where I'd like to focus on some other activities and believe that now is an excellent time to begin to transition the leadership of the Company. I feel tremendously proud of the organization at STAAR and believe that the Company is in a great position to continue its financial growth and maximize shareholder value."
About
STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." More than 450,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 335 full time employees and markets lenses in over 60 countries. Headquartered in
Safe Harbor
All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: any projections of earnings, revenue, sales or any other financial items. Important additional factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's Annual Report on Form 10-K for the year ended
These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements.
CONTACT: |
Investors |
Media |
EVC Group |
EVC Group |
|
Doug Sherk |
Nicole Kruse |
|
415-652-9100 |
212-850-6025 |
SOURCE